Creating new protein-based drugs at scale

Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.

Team Size:6
Location:Munich, Germany
Group Partner:Surbhi Sarna

Active Founders

Patrick Grossmann

My hearts are entrepreneurship & science, originally trained as bioinformatician at the Harvard Medical School and ETH Zurich amongst other schools. I earned a PhD and MBA, and highly enjoy opportunities to improve the world with science-based products. I co-founded Invitris to radically simplify drug development to stop antibiotic-resistance, which has the potential to become the dominating health-economic challenge in this century.

Patrick Grossmann
Patrick Grossmann

Kilian Vogele

Kilian, the CTO and co-founder of Invitris, is responsible for driving innovation and development within the company. With a PhD in synthetic biology from TUM and a track record of 5 patents, his expertise has been instrumental in creating Invitris' groundbreaking technology.

Kilian Vogele
Kilian Vogele

Company Launches


At Invitris we're creating protein-based drugs, such as the next generation of antibiotics. To do this at scale, we created a platform called Phactory, that can turn DNA into synthetic proteins. Phactory makes the development of novel protein-based drugs 10,000x more efficient and cuts down the material costs by 100x.

Hi everyone! This is Kilian and Patrick from INVITRIS, a Munich-based life science company.

Protein-based drugs are powerful but expensive

While only 2% of all treatments are based on protein-based drugs, these drugs generate 40% of the total drug revenue. One of the reasons why they are so expensive is that you need living cells, like bacteria, to produce them. Handling living cells is error-prone and scales terribly because you have to establish new processes for every new drug.

One platform to synthesize them all

Our universal biotech platform, Phactory, takes DNA and uses it to synthesize proteins in a single step. It mimics the molecular machinery you find in living cells but can be stored in conventional vessels.

This platform is based on Kilian’s groundbreaking research during his PhD, which was honored in the famous magazine Science and was also featured on German national TV!

Our primary focus area is bacteriophages - natural viruses that cannot attack humans but bacteria, even when those have become resistant to antibiotics. We are therefore tackling a problem that is expected to cause 25% more deaths per year than all cancers combined in the next decades: multidrug-resistant infections.

We believe in collaboration and partnering!

Building new protein-based products is hard. We can help each other.

  • We are constantly looking for biopharmaceutical partners seeking innovation!
  • Intros to companies developing antibacterial products in animal health or agriculture are also welcome!
  • If you struggle with protein synthesis in general - we can help!
  • Know anyone who is experienced in scaling cell-free expression under GMP? Reach out!

Any outreach is highly appreciated:https://invitris.com/contact/